Njengamanje, inkampani isiqede umsebenzi ofanele wokucwaningwa kwemitholampilo kwesiGaba II nokulungiswa kwesivivinyo somtholampilo weSigaba III sokulimala kwe-Albenatide. Ngokuya kwemiphumela yokuhlolwa kwecala lokwelashwa okokuqala kanye nezidingo zokuvunyelwa komtholampilo we-Albenatide, kuhlanganiswe nesimo sangempela senkampani, inkampani ikholelwa ukuthi inemibandela yokuqala isivivinyo semitholampilo yesigaba sesi-3 futhi inquma ukuqala isigaba sesivivinyo semitholampilo sesigaba III. .
I-Albenatide iyisidakamizwa esikilasi esingu-1.1 ekwelapheni isifo sikashukela sohlobo II. Kuyinto yokulungiselela okwenziwa isikhathi eside kwe-GLP-1 receptor agonist engalashwa kanye ngesonto, okuthuthukisa kakhulu ukulandela isiguli ngemithi.

Le nkampani yenziwa yisigaba sokuqala sokwelashwa komjovo we-Albenatide esibhedlela sokuqala saseJilin University, kanye nokuhlolwa komtholampilo wokujova isigaba se-Albenatide II ezibhedlela ezingama-28 kubandakanya nePeking University People's Hospital. Ngemuva kokuqedwa kwecala lesigaba II somtholampilo we-Albenatide Injection ngoJuni 7, 2019, inkampani yaqhubeka nokuhlaziya izibalo nokuhlanganiswa kwemininingwane efanele yocwaningo. Kuze kube manje, inkampani isiqede ucwaningo lokwelashwa kwesigaba II oluhlobene nomjovo we-Albenatide. Imiphumela yesivivinyo sokwelashwa kwesigaba II somjovo we-Albenatide sikhombisa ukuthi ukuphela okuyikhona kwesivivinyo sokwelashwa kwesigaba II kufinyelelwe.